FI971732L - Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi - Google Patents

Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi Download PDF

Info

Publication number
FI971732L
FI971732L FI971732A FI971732A FI971732L FI 971732 L FI971732 L FI 971732L FI 971732 A FI971732 A FI 971732A FI 971732 A FI971732 A FI 971732A FI 971732 L FI971732 L FI 971732L
Authority
FI
Finland
Prior art keywords
antitoxin
difficile
vaccine
treat
disease caused
Prior art date
Application number
FI971732A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971732A7 (fi
FI971732A0 (fi
Inventor
James A Williams
Nisha V Padhye
John A Kink
Bruce S Thalley
Douglas C Stafford
Joseph R Firca
Original Assignee
Ophidian Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/405,496 external-priority patent/US5919665A/en
Priority claimed from US08/480,604 external-priority patent/US5736139A/en
Application filed by Ophidian Pharm Inc filed Critical Ophidian Pharm Inc
Publication of FI971732A0 publication Critical patent/FI971732A0/fi
Publication of FI971732A7 publication Critical patent/FI971732A7/fi
Publication of FI971732L publication Critical patent/FI971732L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI971732A 1994-10-24 1995-10-23 Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi FI971732L (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32915494A 1994-10-24 1994-10-24
US08/405,496 US5919665A (en) 1989-10-31 1995-03-16 Vaccine for clostridium botulinum neurotoxin
US42271195A 1995-04-14 1995-04-14
US08/480,604 US5736139A (en) 1989-10-31 1995-06-07 Treatment of Clostridium difficile induced disease
PCT/US1995/013737 WO1996012802A1 (en) 1989-10-31 1995-10-23 Vaccine and antitoxin for treatment and prevention of c. difficile disease

Publications (3)

Publication Number Publication Date
FI971732A0 FI971732A0 (fi) 1997-04-23
FI971732A7 FI971732A7 (fi) 1997-06-23
FI971732L true FI971732L (fi) 1997-06-23

Family

ID=27502393

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971732A FI971732L (fi) 1994-10-24 1995-10-23 Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi

Country Status (17)

Country Link
US (1) US6290960B1 (cs)
EP (2) EP0796326A4 (cs)
JP (2) JP2002514886A (cs)
CN (1) CN1176658A (cs)
AT (1) ATE366312T1 (cs)
AU (1) AU709586B2 (cs)
BR (1) BR9509903A (cs)
CA (1) CA2203504A1 (cs)
CZ (1) CZ296806B6 (cs)
DE (1) DE69535530D1 (cs)
FI (1) FI971732L (cs)
HU (1) HUT78048A (cs)
MX (1) MX9702955A (cs)
NO (1) NO323305B1 (cs)
NZ (2) NZ295998A (cs)
PL (1) PL320214A1 (cs)
WO (1) WO1996012802A1 (cs)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
WO1998008540A1 (en) * 1996-08-28 1998-03-05 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for clostridium botulinum neurotoxin
WO1998011229A2 (en) * 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US7179611B2 (en) * 1997-02-10 2007-02-20 Bd Lee Laboratories Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A
EP1000155A1 (en) * 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP2305293A3 (en) 1997-10-20 2013-11-06 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6780617B2 (en) 2000-12-29 2004-08-24 Chen & Chen, Llc Sample processing device and method
CA2337438A1 (en) * 1998-07-13 2000-01-20 Parkash S. Gill Novel inhibitors of angiogenesis and tumor growth
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2000061762A1 (en) * 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
EP1057895A1 (de) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
FR2796385A1 (fr) * 1999-07-16 2001-01-19 Inst Nat Sante Rech Med Methode de production d'anticorps dans le jaune d'oeuf et utilisation des anticorps ainsi obtenus
GB9921592D0 (en) 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CA2460192C (en) 2001-09-11 2011-04-19 Iquum, Inc. Sample vessels
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
EP1603674B1 (en) 2003-02-05 2016-01-06 Iquum, Inc. Sample processing
US9701737B2 (en) * 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
ES2643760T3 (es) 2004-02-06 2017-11-24 University Of Massachusetts Anticuerpos contra toxinas de Clostridium difficile y usos de los mismos
AU2005271372B2 (en) * 2004-08-04 2012-05-03 Allergan, Inc. Optimizing expression of active botulinum toxin type A
NZ555339A (en) * 2004-11-24 2010-03-26 Techlab Inc Device and method for detection of analytes
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
CN100564527C (zh) * 2006-10-23 2009-12-02 中国人民解放军军事医学科学院生物工程研究所 A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
JP2008169142A (ja) * 2007-01-11 2008-07-24 Osaka Prefecture Univ 食中毒菌に対する抗体の産生方法
US9802988B2 (en) 2009-05-20 2017-10-31 University Of Maryland, Baltimore Engineered type IV pilin of Clostridium difficile
EP2432500A4 (en) * 2009-05-20 2014-03-26 Univ Maryland MANIPULATED TYPE IV PILIN OF CLOSTRIDIUM DIFFICILE
WO2011068953A2 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
SMT201700124T1 (it) * 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
CN102181457B (zh) * 2011-03-21 2012-07-04 王世霞 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗
RU2754446C2 (ru) 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
SI3564378T1 (sl) 2011-05-27 2024-02-29 Glaxosmithkline Biologicals Sa Imunogena sestava
WO2013082298A2 (en) * 2011-11-30 2013-06-06 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
KR20140101835A (ko) 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104884081A (zh) 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
EP2969012A4 (en) 2013-03-12 2016-09-14 Univ Yale COMPOSITIONS AND METHODS FOR IDENTIFYING SEQUENCEL ANTIBODY-BONDED MICROBES
WO2015197737A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
EP3188741A4 (en) * 2014-08-28 2018-03-28 Yale University Compositions and methods for the treating an inflammatory disease or disorder
US11433146B2 (en) 2015-06-12 2022-09-06 Vaxart, Inc. Formulations for small intestinal delivery of RSV and norovirus antigens
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
JP6612807B2 (ja) * 2017-03-29 2019-11-27 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
JP6964623B2 (ja) * 2017-03-29 2021-11-10 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
CN108822211B (zh) * 2018-06-05 2019-12-24 中国人民解放军军事科学院军事医学研究院 一种制备a、b、e、f型四价肉毒抗毒素的方法
JP2022513077A (ja) * 2018-11-16 2022-02-07 マトリバックス，インコーポレーテッド クロストリジウム・ディフィシル多成分ワクチン
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
DE3689717T2 (de) 1985-11-25 1994-10-20 Gen Corp Kk Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung.
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5268295A (en) * 1991-05-31 1993-12-07 W. Alton Jones Cell Science Center, Inc. Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
JP4102432B2 (ja) * 1992-09-01 2008-06-18 メルク パテント ゲーエムベーハー 杉花粉由来のアレルゲン性蛋白質及びペプチド
EP0593176A3 (en) * 1992-09-28 1995-03-01 Wisconsin Alumni Res Found Pharmaceutical compositions containing botulinum toxin and method of manufacture.
JPH06192296A (ja) * 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
US5480972A (en) * 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen

Also Published As

Publication number Publication date
JP3914484B2 (ja) 2007-05-16
EP1041149A2 (en) 2000-10-04
EP0796326A1 (en) 1997-09-24
CZ296806B6 (cs) 2006-06-14
US6290960B1 (en) 2001-09-18
BR9509903A (pt) 1997-11-25
ATE366312T1 (de) 2007-07-15
NZ337543A (en) 2002-06-28
FI971732A7 (fi) 1997-06-23
CN1176658A (zh) 1998-03-18
NO971868D0 (no) 1997-04-23
EP0796326A4 (en) 2000-01-19
HUT78048A (hu) 1999-07-28
DE69535530D1 (de) 2007-08-16
EP1041149B8 (en) 2007-10-03
WO1996012802A1 (en) 1996-05-02
AU3968395A (en) 1996-05-15
NO971868L (no) 1997-06-24
AU709586B2 (en) 1999-09-02
WO1996012802A9 (en) 1999-09-16
EP1041149A3 (en) 2001-05-02
CA2203504A1 (en) 1996-05-02
MX9702955A (es) 1998-07-31
FI971732A0 (fi) 1997-04-23
JP2003137897A (ja) 2003-05-14
CZ125097A3 (cs) 1998-03-18
JP2002514886A (ja) 2002-05-21
NO323305B1 (no) 2007-03-05
EP1041149B1 (en) 2007-07-04
NZ295998A (en) 1999-10-28
PL320214A1 (en) 1997-09-15

Similar Documents

Publication Publication Date Title
FI971732L (fi) Rokote ja antitoksiini C. difficilen aiheuttaman taudin hoitamiseksi ja estämiseksi
FI951164L (fi) Respiratory syncytial -viruksen vastaiset neutraloivat ihmisen monoklonaaliset vasta-aineet
NO930699D0 (no) Hoeyeffektiv vaeske/vaeske hydrosyklon
EP0777497A4 (en) HUMAN MONOCLONAL ANTIBODIES NEUTRALIZING THE HUMAN IMMUNIDE DEFICIENCY VIRUS
DE69113205D1 (de) Transdermales therapeutisches System.
NO914538D0 (no) Avfoeler for samtidig dobbelt betraktningsfelt
DK1382348T3 (da) Polynukleotidvaccineformulering, især til behandling af bovin luftvejssygdom
FI933770A7 (fi) Farmaseuttisia koostumuksia ihotautien hoitamiseen
TR199501635A1 (tr) Solunum yolu ile alinan terapötik preparatlar.
FI953899A7 (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
FI912060A0 (fi) Med aktiv stroemavbrytning foersedd spaenningsregulator.
FI20070041L (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
NL300112I1 (nl) Vaccin tegen dermatomycosis.
IT231046Y1 (it) Massaggiatrice per prosciutti crudi.
IT1279028B1 (it) Insetticida che vaporizza a caldo, producente esalazioni, per uccidere mosche
FI963753L (fi) Uusi lääke hengitysteiden virustaudin hoitamiseksi
FI950649L (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
KR950027629U (ko) 모자다리는 장치
KR960000327U (ko) 무병장수하는 신선침제조방법
KR960020176U (ko) 한방 의술용 침구
FI915299A0 (fi) Processarrangemang foer den korta cirkulationen i en pappersmaskin.
FR2694702B3 (fr) Bracelet therapeutique perfectionne.
KR930702972A (ko) 신질환치료제
KR960019820U (ko) 결합이 용이한 상다리
ES1015200Y (es) Mosquitera perfeccionada.